依维莫司与贝伐单抗治疗复发性、进展性颅内NF2突变型脑膜瘤
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma.
作者信息
Mathew Thomas Vinay, Bindal Poorva, Vredenburgh James J
机构信息
Department of Internal Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.
Department of Hematology-Oncology, Smilow Cancer Center Yale-New Haven at Saint Francis, Hartford, Connecticut, USA.
出版信息
Case Rep Oncol. 2019 Jan 30;12(1):126-130. doi: 10.1159/000496984. eCollection 2019 Jan-Apr.
Meningiomas are primary CNS tumors that arise from the arachnoid layer of the meninges. Genomic sequencing has revealed that NF2 mutations are the most common genetic alteration seen in meningiomas. Meningiomas although usually low grade, can sometimes progress to high grade. A patient who had several recurrences of meningiomas since childhood presented with recurrent headaches. Imaging showed that he had another recurrence of a meningioma. He underwent surgery for resection of the meningioma and histopathology showed NF2 mutation. He was started on everolimus and bevacizumab with good effect. Studies have shown that NF-2 mutated meningiomas have a good response to everolimus and bevacizumab with increased progression-free survival time and progression-free survival time at 6 months.
脑膜瘤是起源于脑膜蛛网膜层的原发性中枢神经系统肿瘤。基因组测序显示，NF2突变是脑膜瘤中最常见的基因改变。脑膜瘤虽然通常为低级别，但有时会进展为高级别。一名自童年起就多次复发脑膜瘤的患者出现了复发性头痛。影像学检查显示他又一次出现了脑膜瘤复发。他接受了脑膜瘤切除术，组织病理学检查显示存在NF2突变。他开始使用依维莫司和贝伐单抗治疗，效果良好。研究表明，NF-2突变的脑膜瘤对依维莫司和贝伐单抗反应良好，无进展生存期和6个月时的无进展生存期均有所延长。
Zotero 插件